Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | CA2 | P00918 | 2/20 | 0.56 |
| ▸ | IDO1 | P14902 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.46 |
| ▸ | ABAT | P80404 | 1/20 | 0.46 |
| ▸ | NQO1 | P15559 | 1/20 | 0.44 |
| ▸ | ESR1 | P03372 | 2/20 | 0.44 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.44 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.43 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.43 |
| ▸ | CA4 | P22748 | 1/20 | 0.43 |
| ▸ | CA6 | P23280 | 1/20 | 0.43 |
| ▸ | CA5A | P35218 | 1/20 | 0.43 |
| ▸ | CA7 | P43166 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30437401 | 0.93 | KMT2A (0.50) | MEN1KMT2ACA2IDO1LMNA | |
| SCHEMBL147245 | 0.84 | KMT2A (0.44) | MEN1KMT2ALMNAALDH1A1SLC6A2 | |
| SCHEMBL5709288 | 0.84 | TPSAB1 (0.51) | MEN1KMT2AABATALDH1A1 | |
| SCHEMBL1934595 | 0.84 | KMT2A (0.44) | MEN1KMT2ACA2LMNANQO1 | |
| SCHEMBL5762294 | 0.83 | MAOB (0.54) | MEN1KMT2AIDO1LMNAKDM4E | |
| SCHEMBL436380 | 0.83 | KMT2A (0.42) | MEN1KMT2ACA2LMNANQO1 | |
| SCHEMBL17080518 | 0.83 | CYP3A4 (0.54) | MEN1KMT2AIDO1 | |
| SCHEMBL2297635 | 0.83 | PARP10 (0.54) | CA2CA9KDM4EALDH1A1L3MBTL1 | |
| SCHEMBL21385042 | 0.83 | KMT2A (0.42) | MEN1KMT2ACA2LMNANQO1 | |
| SCHEMBL113937 | 0.83 | IDO1 (0.54) | MEN1KMT2ACA2IDO1CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114126619-B | Compounds for the synthesis of peptidomimetics | 范因斯坦医学研究院 | 2024-03-15 | — | — | CN | claimed |
| CN-114126619-A | Compounds for the synthesis of peptidomimetics | 范因斯坦医学研究院 | 2022-03-01 | — | — | CN | claimed |
| US-8796229-B2 | Feedback prodrug | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2014-08-05 | — | — | US | claimed |
| CN-121428061-A | High-selectivity butyrylcholinesterase inhibitor from moringa seed extract as well as screening method and application thereof | 北京中医药大学 | 2026-01-30 | — | — | CN | disclosed |
| WO-2024059186-A1 | N-((ISOQUINOLIN-6-YL)METHYL)-1H-PYRAZOLE-4-CARBOXAMID DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS FOR THE TREATMENT OF HEREDITARY ANGIOEDEMA | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-03-21 | — | — | WO | disclosed |
| CN-114126619-B | Compounds for the synthesis of peptidomimetics | 范因斯坦医学研究院 | 2024-03-15 | — | — | CN | disclosed |
| CN-117677606-A | 2-carboxy-indole inhibitors of metallo-beta-lactamase | 牛津大学创新有限公司 | 2024-03-08 | — | — | CN | disclosed |
| CN-117642397-A | Modified proteins and protein binders | 上海睿跃生物科技有限公司 | 2024-03-01 | — | — | CN | disclosed |
| CN-117615794-A | Checkpoint inhibitors conjugated to IL-2 and uses thereof | 明峰治疗股份公司 | 2024-02-27 | — | — | CN | disclosed |
| CN-117615792-A | Conjugates of checkpoint inhibitors with IL-2 and uses thereof | 明峰治疗股份公司 | 2024-02-27 | — | — | CN | disclosed |
| CN-117615793-A | Antibody conjugates and their preparation | 明峰治疗股份公司 | 2024-02-27 | — | — | CN | disclosed |
| US-8796229-B2 | Feedback prodrug | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2014-08-05 | — | — | US | disclosed |
| US-8470776-B2 | Conjugates of disorazoles and their derivatives with cell-binding molecules, novel disorazole derivatives, processes of manufacturing and uses thereof | AETERNA ZENTARIS GMBH (DE) | 2013-06-25 | — | — | US | disclosed |
| US-20130035484-A1 | INTERMEDIATES USEFUL FOR THE SYNTHESIS OF PYRROLOBENZODIAZEPINES | SPIROGEN DEVELOPMENTS SÀRL (CH) | 2013-02-07 | — | — | US | disclosed |
| US-20120058960-A1 | FEEDBACK PRODRUG | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2012-03-08 | — | — | US | disclosed |
| US-20100160207-A1 | Feedback Prodrug | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2010-06-24 | — | — | US | disclosed |
| EP-1900742-A1 | Conjugates of disorazoles and their derivatives with cell-binding molecules, novel disorazole derivatives, processes of manufacturing and uses thereof | AEterna Zentaris GmbH (DE) | 2008-03-19 | — | — | EP | disclosed |
| WO-2008028934-A1 | CONJUGATES OF DISORAZOLES AND THEIR DERIVATIVES WITH CELL-BINDING MOLECULES, NOVEL DISORAZOLE DERIVATIVES, PROCESSES OF MANUFACTURING AND USES THEREOF | AETERNA ZENTARIS GMBH (DE) | 2008-03-13 | — | — | WO | disclosed |
| WO-2007098033-A2 | FEEDBACK PRODRUG | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC . (US) | 2007-08-30 | — | — | WO | disclosed |
| CN-1798729-A | Benzamide nitrile derivatives | HOFFMANN LA ROCHE (CH) | 2006-07-05 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130035484-A1 | INTERMEDIATES USEFUL FOR THE SYNTHESIS OF PYRROLOBENZODIAZEPINES | CYP11B2, CYP1B1, CYP11B1 | MEN1 1060/4885KMT2A 1249/4885CA2 4220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.